Anavex confirms positive efficacy Phase2 Alzheimer’s trial for its Anavex 2-73 datahad

Anavex has confirmed the information about positive safety and cognitive efficacy data from the Phase 2a Alzheimer’s trial for ANAVEX 2-73.

Anavex, in a press release issued Wednesday, said that there has been no change with regards to its science, data or the fundamentals of the company.

The company said:

“We remain dedicated to advancing ANAVEX 2-73 through the ongoing Phase 2a trial and to reporting new data to investors as it becomes available”

Anavex said in its news release dated November 9, 2015, that investigators presented positive safety and cognitive efficacy data for ANAVEX 2-73, the its lead investigational oral treatment for Alzheimer’s disease targeting sigma-1 and muscarinic receptors. According to Anavex, they can reduce protein misfolding including reduction of beta amyloid, tau protein and inflammation at the international CTAD 2015 conference in Barcelona, Spain.

As the company had said, initial analysis of Phase 2a data demonstrated that the study met the primary objective of safety as ANAVEX 2-73 was well tolerated and results were consistent with prior Phase 1 clinical trial data. The secondary objectives were also met, with ANAVEX 2-73 showing cognitive improvement across all doses in all exploratory cognitive measurements, including the Cogstate battery, Mini Mental State Examination (MMSE), event-related potentials (ERP) and P300 tests, which consistently demonstrated improvements from baseline in the completed PART A portion of the study in 32 mild-to-moderate Alzheimer’s patients.

Even though PART A was designed as a 5 week bioavailability trial that included a built-in wash-out period of 12 days and without an optimized dosing regimen, Anavex had said that several Cogstate tests demonstrated highly statistically significant improvements.

“This finding was supported by a trend towards improvement in median MMSE score, which increased by +1.5 over baseline at week 5,” the company had concluded.